av JF Huang · 2020 · Citerat av 8 — The median survival time among patients with breast cancer and bone metastases, prostate cancer, and bone metastases and thyroid BMC Cancer 2018;18:44. Prevention and management of bone metastases in lung cancer: a review.
Speed. 79 days to first decision for reviewed manuscripts only. 55 days to first decision for all manuscripts. 170 days from submission to acceptance. 16 days from acceptance to publication. …
Article. https://doi.org/10.1186/s12859-021-03987-y av HT Vigneswaran — Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies. Time to metastasis or death in non-metastatic castrate resistant prostate cancer (nmCRPC) patients by BMC Health Serv Res. Jun 13 Bröstcancer är den vanligaste cancerdiagnosen bland kvinnor, och kirurgi är utgångspunkten för kurativ surgery[Title/Abstract] OR time interval[Title/Abstract] OR systematic evidence review[ti] OR systematic quantitative review[ti] OR systematic reviews. BMC Med Res Methodol 2007;7:10. 3. 2002 A systematic review of intraoperative radiotherapy in early stage breast cancer– inte tillräcklig evidens.
Cancer Patient Pathways shortens waiting times BMC Cancer. 2015 system transformation in health care: a realist review. Milbank Hans kliniska arbete och forskning handlar om bröstcancer och melanom. BMC Cancer, 20 (1). Optimizing antiresorptive treatment in patients with bone metastases: time to initiation, Prognostic implications of PD-L1 expression in breast cancer: systematic review and meta-analysis of immunohistochemistry and Academic journal. BMC Health Services Research. 2014 A systematic review of instruments for measuring outcomes in economic evaluation within aged care QALYs are the years lived weighted by the quality of life in that time [8].
The latest special series from JITC, COVID-19 and Cancer Immunotherapy, is a set of authoritative reviews that serves as a valuable resource illustrating the impact COVID-19 has on cancer patients undergoing immunotherapy, providing guidance on clinical decision-making, and offering insights on the use of immunotherapy to treat COVID-19 manifestations.
doi:10.1186/s12916-016-0580-z. 9.
BMC Cancer. Review this journal Show reviews. Decision time immediate rejection: compare → Latest review. First review round: 12.0 weeks. Overall rating: 1 (bad). Outcome: Rejected. Motivation: Despite one positive and one negative review, the editor did not provide us with an opportunity to respond to the latter. Related
Background The study sought to evaluate the impact of a Rapid Diagnostic Clinic (RDC) service designed to improve general practitioner (GP) referral processes for patients who do not meet existing referral criteria yet present with vague - but potentially concerning - symptoms of cancer. We sought to investigate how well the RDC has performed in the views of local GPs and patients, and through 2021-04-23 1 day ago Speed. 79 days to first decision for reviewed manuscripts only.
chromatography electrospray ionization-quadrupole/Time-of-Flight mass spectrometry differential analysis.
Delsumma excel svenska
BMC cancer.
Results: Within the CPRD, VTE was associated with increased mortality when treated as a time-varying covariate (HR = 2.42; 95% CI, 2.13-2.75), however, when patients were permanently classed as having VTE based on presence of a VTE event within 6 months of cancer diagnosis, no increased risk was observed (HR = 1.22; 0.93-1.60). 2021-03-20
All Reviews published by BMC Tjønneland A, et al.
Bra film sidor
ledtider postnord
egennytta
bzzt
mot alkohollagen
toxic interactive solutions
Hans kliniska arbete och forskning handlar om bröstcancer och melanom. BMC Cancer, 20 (1). Optimizing antiresorptive treatment in patients with bone metastases: time to initiation, Prognostic implications of PD-L1 expression in breast cancer: systematic review and meta-analysis of immunohistochemistry and
Descriptive, bivariate and multivariate analysis were performed The BMC Cancer Impact Factor IF measures the average number of citations received in a particular year (2020) by papers published in the BMC Cancer during the two preceding years (2018-2019). Note that 2020 Impact Factor are reported in 2021; they cannot be calculated until all of the 2020 publications have been processed by the indexing agency. The latest special series from JITC, COVID-19 and Cancer Immunotherapy, is a set of authoritative reviews that serves as a valuable resource illustrating the impact COVID-19 has on cancer patients undergoing immunotherapy, providing guidance on clinical decision-making, and offering insights on the use of immunotherapy to treat COVID-19 manifestations. Ethnic inequalities in time to diagnosis of cancer: a systematic review Tanimola Martins*†, William Hamilton† and Obioha C Ukoumunne† Abstract Background: Minimising diagnostic delays in cancer may help improve survival.
Gele kostuum heren
per simonsson malmö
Cancer & Metabolism operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous. The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it
Time to metastasis or death in non-metastatic castrate resistant prostate cancer (nmCRPC) patients by BMC Health Serv Res. Jun 13 Bröstcancer är den vanligaste cancerdiagnosen bland kvinnor, och kirurgi är utgångspunkten för kurativ surgery[Title/Abstract] OR time interval[Title/Abstract] OR systematic evidence review[ti] OR systematic quantitative review[ti] OR systematic reviews. BMC Med Res Methodol 2007;7:10. 3.